 |
|
|
|
|
|
|
Pharmaceuticals
Canada Products |
|
|
|
|
|
 |
|
|
|
|
|
Actonel ® |
|
|
|
|
|
Asacol ® |
|
|
|
|
|
Asacol® 800 |
|
|
|
|
|
Dantrium ®
Capsules |
|
|
|
|
|
Dantrium ®
Intravenous |
|
|
|
|
|
Didrocal ® |
|
|
|
|
|
Didronel ® |
|
|
|
|
|
Macrobid ® |
|
|
|
|
|
Seasonale ® |
|
|
|
|
|
Zomig ® |
|
|
|
|
|
|
|
|
|
|
|
|
|
History:
- 1970
P&G's pharmaceutical business begins with specialty products group
yielding products in United States such as Didronel for the treatment
of Paget's disease.
- 1982
P&G acquires Norwich Eaton Pharmaceuticals. Provides innovative
Research & Development and prescription products such as Macrodantin
for treatment of urinary tract infections, and Dantrium for treatment
of malignant hyperthermia.
- 1980’s
P&G expands R&D facilities and focuses research on three core
areas: anti-infectives, bone metabolism and cardiac health. P&G
Pharmaceuticals strengthens marketing presence in international markets.
- Late 1980 - 90’s
Completion of strategic international acquisitions of Nativelle (France),
Rohm Pharma (Germany), and Smith, Kline and French brands (Italy.)
- 1992
P&G's pharmaceutical business officially named Procter & Gamble
Pharmaceuticals
- 1995
Didrocal approved for osteoporosis in Canada
Phase III trials of Azimilide (cardiac antiarrhythmic) were initiated.
- 1997
P&G Pharmaceuticals entered into major agreements with:
HMR - an alliance to commercialize risedronate
Regeneron - collaboration to discover and develop new products
Watson Laboratories - partnership to develop new hormone replacement
therapy products for women
- 2000
Actonel approved for osteoporosis in Canada
Phase IIb trials of Intrinsa (transdermal testosterone) were intiated
- 2002
P&G Pharmaceuticals reaches $1Billion (US) in sales
P&G Pharmaceuticals Canada reaches $120 million in sales
|
|
|
|
|
|
|
